leadf
logo-loader
viewBioSig Technologies, Inc.

BioSig Technologies to begin first-in-human studies of its PURE EP System at the Mayo Clinic

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner said the medical device company will begin its first-in-human studies at the Mayo Clinic using its PURE EP System at its Jacksonville, Florida hospital.

PURE EP was developed by the Los Angeles based company to improve catheter ablation treatments for heart arrhythmias.

Londoner says the company will approach the commercial market next year.

Quick facts: BioSig Technologies, Inc.

Price: 4.99 USD

NASDAQ:BSGM
Market: NASDAQ
Market Cap: $148.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

BioSig teams up with Sorrento Therapeutics to fight the coronavirus with a...

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the group's subsidiary ViralClear Pharmaceuticals, Inc is teaming up with Sorrento Therapeutics, Inc. (NASDAQ: SRNE) to advance the fight against the coronavirus. Londoner says the two biotechs will look at the effective...

3 weeks, 1 day ago

2 min read